InsiderPulse
← 10-K / 10-Q
10-QAKTX

Akari Therapeutics Plc

Filed 2026-05-19Period ending 2026-03-31
EDGAR ↗All periods →

Income Statement

Line Item2026-03-31Q/QY/Y
R&D Expense$1.5M+79.5%
SG&A Expense$2.2M-20.0%
Operating Income-$15.8M-347.0%
Pre-tax Income-$15.3M-313.3%
Income Tax-$859K
Net Income-$14.5M-290.1%
EPS (Basic)$0.00
EPS (Diluted)$0.00

Balance Sheet

Line Item2026-03-31Q/QY/Y
Cash & Equivalents$2.8M+7.2%
Current Assets$3.6M-34.3%+7.2%
Total Assets$33.9M-29.2%-33.5%
Current Liabilities$13.4M+8.6%-35.8%
Total Liabilities$19.5M-0.3%-33.2%
Stockholders' Equity$14.4M-49.2%-33.9%

Cash Flow

Line Item2026-03-31Q/QY/Y
Operating Cash Flow-$2.5M-15.7%
Financing Cash Flow$53K-97.5%